– Expected overall cash savings of $75 million through 2025
– New executive management team in place
SAN DIEGO, July 24, 2023 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced a cost reduction plan and a corporate restructuring, following a strategic review of the business conducted by the new management team. These actions are expected to result in cash savings of approximately $75 million through 2025, inclusive of $45 million in operational savings, and continue Heron’s progression towards a streamlined organization focused on commercial executio…
Read the full article at: https://www.prnewswire.com/news-releases/heron-therapeutics-announces-cost-reduction-plan-and-restructuring-301883631.html